Milestone Scientific Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Arjan Haverhals

Geschäftsführender

US$680.3k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	51.5%
Amtszeit als Geschäftsführer	3.8yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.3yrs

Jüngste Management Updates

Recent updates

Did You Miss Milestone Scientific's (NYSEMKT:MLSS) Whopping 317% Share Price Gain?

Feb 23

Here's What Milestone Scientific Inc.'s (NYSEMKT:MLSS) Shareholder Ownership Structure Looks Like

Dec 15

Earnings Update: Here's Why Analysts Just Lifted Their Milestone Scientific Inc. (NYSEMKT:MLSS) Price Target To US$4.00

Nov 19

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Arjan Haverhals im Vergleich zu den Einnahmen von Milestone Scientific verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$680k	US$350k	-US$7m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$7m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$841k	US$350k	-US$9m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$735k	US$319k	-US$7m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$6m
Mar 31 2021	n/a	n/a	-US$7m
Dec 31 2020	US$359k	US$157k	-US$7m

Vergütung im Vergleich zum Markt: ArjanDie Gesamtvergütung ($USD680.27K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD673.68K).

Entschädigung vs. Einkommen: ArjanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Arjan Haverhals (62 yo)

3.8yrs

Amtszeit

US$680,265

Vergütung

Mr. Jan Adriaan Haverhals, also known as Arjan, serves as Chief Executive Officer and Director at Milestone Medical, Inc. since June 2021 and 2023 respectively. Mr. Haverhals has been President of Mileston...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jan Haverhals	President	1.5yrs	US$680.27k	keine Daten
Leonard Osser	Founder & Vice Chairman	33yrs	US$100.00k	3.7% $ 1.9m
Neal Goldman	Independent Chairman of the Board	5.3yrs	US$120.00k	2.84% $ 1.4m
Paul Davis	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Benedetta Casamento	Independent Director	2.3yrs	US$120.00k	0.35% $ 177.9k
Ralf Gebhard	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Lorrence Green	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Gian Trombetta	Independent Director	10.2yrs	US$100.00k	13.11% $ 6.7m
Michael McGeehan	Independent Director	6.8yrs	US$110.00k	0.65% $ 333.5k
Olivier Choquet	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Didier Demesmin	Independent Director	less than a year	keine Daten	keine Daten

5.3yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: MLSSDie Vorstandsmitglieder gelten als erfahren (5.2 Jahre durchschnittliche Amtszeit).

Milestone Scientific Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Milestone Scientific Inc., Annual General Meeting, Jul 16, 2024

Director notifies of intention to sell stock

Less than half of directors are independent

Milestone Scientific Inc. Appoints Didier Demesmin to Board of Directors

Milestone Scientific Inc. Announces Resignation of Peter J. Milligan as Chief Financial Officer, Effective September 1, 2023

Milestone Scientific Inc. Announces the Appointment of Peter Milligan as the Chief Financial Officer

Recent updates

Milestone Scientific Receives Regulatory Approval to Market Compuflo Epidural System in Brazil

Milestone Scientific Inc., Annual General Meeting, Jul 16, 2024

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates decrease by 10%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Milestone Scientific Inc. has completed a Follow-on Equity Offering in the amount of $3.00195 million.

New minor risk - Shareholder dilution

Milestone Scientific Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 13%

New major risk - Financial position

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Director notifies of intention to sell stock

Less than half of directors are independent

Milestone Scientific Inc. Appoints Didier Demesmin to Board of Directors

Milestone Scientific Inc. Announces Resignation of Peter J. Milligan as Chief Financial Officer, Effective September 1, 2023

Consensus EPS estimates fall by 29%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Consensus estimates of losses per share improve by 12%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Milestone Scientific Inc. Announces the Appointment of Peter Milligan as the Chief Financial Officer

Milestone Scientific Inc. Announces Board Changes

Milestone Scientific Inc. Appoints Neal Goldman as Chairman of the Board of Directors

Leonard M. Schiller Tenders His Resignation to Milestone Scientific Inc. as A Director

Insufficient new directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Milestone Scientific Inc. Reports Commencement of Sales of its CompuFlo(R) Epidural Instrument Disposables at a Leading Veterinary and Academic Institution

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

Milestone Scientific Inc., Annual General Meeting, Jun 13, 2022

Price target decreased to US$4.00

Price target decreased to US$4.00

Founder notifies of intention to sell stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Founder notifies of intention to sell stock

Milestone Scientific Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Founder exercised options to buy US$268k worth of stock.

Third quarter 2021 earnings released: US$0.029 loss per share (vs US$0.023 loss in 3Q 2020)

Founder exercised options to buy US$417k worth of stock.

Independent Chairman of the Board notifies of intention to sell stock

Independent Chairman of the Board recently sold US$86k worth of stock

Consensus EPS estimates fall to -US$0.11

Second quarter 2021 earnings released: US$0.039 loss per share (vs US$0.056 loss in 2Q 2020)

Chief Financial Officer Scott Kahn has left the company

Milestone Scientific Inc.(NYSEAM:MLSS) dropped from Russell 3000E Value Index

Consensus forecasts updated

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.032 loss in 1Q 2020)

Consensus revenue estimates increase to US$10.3m

Full year 2020 earnings released: US$0.12 loss per share (vs US$0.17 loss in FY 2019)

Milestone Scientific Receives Notice of Allowance for European Patent Related to Combination of Nerve Stimulation and Dps Dynamic Pressure Sensing Technology® to Optimize Needle Tip Location in Ultrasound-Guided Pnb Procedures

Milestone Scientific Inc. Commences Sales of CompuFlo® / CathCheck™ Disposables to the Nationally Recognized Medical University of South Carolina

New 90-day high: US$4.13

Did You Miss Milestone Scientific's (NYSEMKT:MLSS) Whopping 317% Share Price Gain?

Independent Chairman of the Board notifies of intention to sell stock

Analysts update estimates

Independent Chairman of the Board recently sold US$169k worth of stock

Milestone Scientific Inc. Adds Three Additional Premier Distributors Providing Robust U.S. Coverage and A New Distributor in Canada for the Company’S Dental Instrument

Milestone Scientific Inc. Signs Two Additional Distribution Agreements with Atlanta Dental and Nashville Dental for its Wand Single Tooth Anesthesia System

New 90-day high: US$3.48

Director recently sold US$215k worth of stock

Milestone Scientific Inc. Receives Notice of Allowance for U.S Patent Related to Compuflo® Disposables

New 90-day high: US$2.90

Milestone Scientific Inc. Announces It Has Begun Implementing Three-Year Strategy to Expand the World-Wide Global Dental Market

Milestone Scientific Inc. Announces Agreement with Bitmedical AG to Distribute the CompuFlo® Epidural Instrument Across Austria and Switzerland

Milestone Scientific Inc. Raises Revenue Guidance for Fourth Quarter 2020

Founder exercised options to buy US$183k worth of stock.